Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

abstract：:Our growing physiological understanding of hematopoietic progenitor cells has led to the clinical use of circulating progenitor cells, including stem cells, for either reconstitution of hematopoietic function, up to the transduction of functional genes into a self-renewing cell system. In the following, an attempt has...

journal_title：Bone marrow transplantation

authors： Körbling M,Fliedner TM

更新日期：1996-05-01 00:00:00

abstract：:Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using...

journal_title：Bone marrow transplantation

authors： Bashey A,Solomon SR

更新日期：2014-08-01 00:00:00

abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

journal_title：Bone marrow transplantation

authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

更新日期：1990-01-01 00:00:00

abstract：:A 16-month-old girl diagnosed with osteopetrosis underwent an unrelated, partially matched (with major mismatch at A locus) cord blood stem cell transplant. Twelve months later she developed severe acute autoimmune hemolytic anemia (AIHA). Immunophenotype analysis of lymphocyte subsets 8 months post transplant showed ...

journal_title：Bone marrow transplantation

authors： Sevilla J,González-Vicent M,Madero L,Díaz MA

更新日期：2001-07-01 00:00:00

abstract：:Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

journal_title：Bone marrow transplantation

authors： Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

更新日期：2015-02-01 00:00:00

abstract：:Peripheral blood progenitor cell (PBPC) populations used for transplantation were analyzed for the presence of CD34+ cells, colony-forming cells (initial CFC), and long-term culture initiating cells (LTC-IC) cultured on irradiated stroma for 5 weeks. Thirty-eight leukapheresis products were studied from 11 patients wi...

journal_title：Bone marrow transplantation

authors： Bender JG,Lum L,Unverzagt KL,Lee W,Van Epps D,George S,Coon J,Ghalie R,McLeod B,Kaizer H

更新日期：1994-04-01 00:00:00

abstract：:Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group...

journal_title：Bone marrow transplantation

authors： Milone G,Poidomani M,Leotta S,Avola G,Camuglia MG,Privitera A,Consoli C,Mercurio S,Romeo MA,Di Marco A,Di Mercurio S,Spadaro A,Palumbo GA,Tedeschi P

更新日期：2012-01-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (allo-HCT) for patients with AML is increasingly able to impact the historically poor outcomes in this disease. Nonetheless, even with transplant, the rates of post-HCT relapse are unacceptably high, and remain a great challenge in the treatment of patients with AML. Maint...

journal_title：Bone marrow transplantation

authors： Brunner AM,Fathi AT,Chen YB

更新日期：2016-11-01 00:00:00

abstract：:In the original version of this article, the mention of 'ifosfamide 1500 mg/m2 days 1-3' should, in fact, read 'ifosfamide 1500 mg/m2 bd days 1-3'. This has now been updated in the original version of the article. ...

journal_title：Bone marrow transplantation

authors： Phillips EH,Lannon MM,Lopes A,Chadwick H,Jones G,Sieniawski M,Davies A,Wood K,Clifton-Hadley L,Smith P,Lawrie A,Chadwick N,Lennard AL

更新日期：2020-04-01 00:00:00

abstract：:Transplant related mortality and relapse after bmt have a negative influence on the outcome of patients transplanted for acute leukaemia in first remission. Transplant related mortality includes graft-versus-host disease, infections and graft failure. To prevent gvhd and associated infections without increased graft r...

journal_title：Bone marrow transplantation

authors： Arnold R,Bunjes D,Wiesneth M,Hertenstein B,Theobald M,Heimpel H,Hale G,Waldmann H

更新日期：1993-01-01 00:00:00

abstract：:Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliov...

journal_title：Bone marrow transplantation

authors： Parkkali T,Stenvik M,Ruutu T,Hovi T,Volin L,Ruutu P

更新日期：1997-10-01 00:00:00

abstract：:A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells. CD34+ selection has been used to purge autografts in MM and it is also possible to reduce tumour cell contamination of autografts by cytotoxic drug therapy prior to peripheral blood stem cell (PB...

journal_title：Bone marrow transplantation

authors： Dyson PG,Horvath N,Joshua D,Barrow L,Van Holst NG,Brown R,Gibson J,To LB

更新日期：2000-06-01 00:00:00

abstract：:This study assessed the incidence of long-term oral complications in 88 survivors of allogeneic haematopoietic cell transplantation (HCT). Patients examined were between 6 months and 6 years post-HCT and aged from 19 to 65 years. Subjects were investigated for both the subjective and objective features of long-term ad...

journal_title：Bone marrow transplantation

authors： Hull KM,Kerridge I,Schifter M

更新日期：2012-02-01 00:00:00

abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

journal_title：Bone marrow transplantation

authors： Thompson JS,Chu Y,Glass JF,Brown SA

更新日期：2010-04-01 00:00:00

abstract：:This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

journal_title：Bone marrow transplantation

authors： Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

更新日期：1990-05-01 00:00:00

abstract：:The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT ...

journal_title：Bone marrow transplantation

authors： Dispenzieri A,Seenithamby K,Lacy MQ,Kumar SK,Buadi FK,Hayman SR,Dingli D,Litzow MR,Gastineau DA,Inwards DJ,Micallef IN,Ansell SM,Johnston PB,Porrata LF,Patnaik MM,Hogan WJ,Gertz MA

更新日期：2013-10-01 00:00:00

abstract：:Activation of donor T cells is required for the development of graft-versus-host disease (GVHD), a major complication of bone marrow transplantation. We investigated a murine model of GVHD across major and minor histocompatibility barriers. BALB/c recipients were lethally irradiated and transplanted with 10(7) bone ma...

journal_title：Bone marrow transplantation

authors： van Leeuwen L,Guiffre A,Atkinson K,Rainer SP,Sewell WA

更新日期：2002-01-01 00:00:00

abstract：:The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requir...

journal_title：Bone marrow transplantation

authors： van der Heiden PL,Kalpoe JS,Barge RM,Willemze R,Kroes AC,Schippers EF

更新日期：2006-04-01 00:00:00

abstract：:When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early a...

journal_title：Bone marrow transplantation

authors： Johnson BD,Drobyski WR,Truitt RL

更新日期：1993-04-01 00:00:00

abstract：:Collection of peripheral blood stem cells (PBSC) does not require anesthesia or multiple marrow aspirations, and hence, is far less invasive than bone marrow collection. Most importantly, PBSC can be collected from the body's entire pool of HSC to provide more stem cells than marrow aspiration performed at localized i...

journal_title：Bone marrow transplantation

authors： Takaue Y,Kawano Y,Watanabe T,Watanabe A

更新日期：1998-12-01 00:00:00

abstract：:The impact of graft-versus-host reactivity on the outcome of bone marrow transplantation (BMT) was analysed in rabbits of defined major histocompatibility (RLA) types by injecting 10(8) parental type cells into newborn F1 recipients. Distinctive allotypic determinants on immunoglobulin (Ig) molecules of donor and reci...

journal_title：Bone marrow transplantation

authors： Adler LT,Annaratone LJ 3rd,LeBeau MM

更新日期：1990-01-01 00:00:00

abstract：:Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during th...

journal_title：Bone marrow transplantation

authors： D'Costa S,Slobod KS,Benaim E,Bowman L,Cunningham J,Holladay M,Howlett N,Srivastava DK,Hurwitz JL

更新日期：2001-09-01 00:00:00

abstract：:High-dose immunoablative chemotherapy with autologous haematopoietic cell support might be beneficial in the treatment of intractable forms of MS. We mobilised PBPC in 11 patients with secondary progressive MS and finally eight patients were grafted after high-dose BEAM chemotherapy with either in vitro or in vivo T c...

journal_title：Bone marrow transplantation

authors： Kozák T,Havrdová E,Pit'ha J,Gregora E,Pytlík R,Maaloufová J,Marecková H,Kobylka P,Vodvárková S

更新日期：2000-03-01 00:00:00

abstract：:We report here the first case of large granular lymphocytes (LGL) expansion following non-myeloablative allo-BMT for chronic myeloid leukemia. We characterized the morphologic, phenotypic and functional features of the LGL subset amplified in vivo 14 months after allo-BMT. Our results indicate that LGL can mediate in ...

journal_title：Bone marrow transplantation

authors： Mohty M,Faucher C,Gaugler B,Vey N,Sainty D,Arnoulet C,Mozziconacci MJ,Isnardon D,Gastaut JA,Maraninchi D,Olive D,Blaise D

更新日期：2001-12-01 00:00:00

abstract：:Four clinical strategies are proposed for the management of CMV disease: prophylaxis, suppression, pre-emptive therapy and treatment. The degree of risk of developing CMV disease and the safety profile of the presently available drugs need to be considered when deciding on the most appropriate approach. We conclude th...

journal_title：Bone marrow transplantation

authors： Prentice HG,Kho P

更新日期：1997-01-01 00:00:00

abstract：:Thirty-five patients with myelodysplastic syndromes (MDS) were treated with BMT between 1986 and 1994. Their median age was 41 years (range 23-60). Thirteen patients had transfusion-dependent refractory anaemia (RA). Twenty-two patients suffered from more advanced stages of MDS, 15 being in complete remission (CR) aft...

journal_title：Bone marrow transplantation

authors： Mattijssen V,Schattenberg A,Schaap N,Preijers F,De Witte T

更新日期：1997-04-01 00:00:00

abstract：SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...

journal_title：Bone marrow transplantation

authors： Dalle JH,Wall D,Theoret Y,Duval M,Shaw L,Larocque D,Taylor C,Gardiner J,Vachon MF,Champagne MA

更新日期：2003-10-01 00:00:00

abstract：:Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction t...

journal_title：Bone marrow transplantation

authors： Biron P,Durand M,Roché H,Delozier T,Battista C,Fargeot P,Spaeth D,Bachelot T,Poiget E,Monnot F,Tanguy ML,Curé H

更新日期：2008-03-01 00:00:00

abstract：:We characterized CD34+ cells purified from bone marrow (BM), mobilized peripheral blood (PB) and cord blood (CB) and we tried to establish correlations between the cell cycle kinetics of the CD34+CD38- and CD34+CD38+ subpopulations, their sensitivity to SCF and IL-3 and their expression of receptors for these two CSFs...

journal_title：Bone marrow transplantation

authors： De Bruyn C,Delforge A,Lagneaux L,Bron D

更新日期：2000-02-01 00:00:00